TGTX
NASDAQ
$53.96
TG Therapeutics Inc (TGTX)
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $58.38 (+8.19%)
Market Cap
$8.64B
PEG Ratio
0.02
Revenue 5Y CAGR
+278.04%
P/E Ratio
18.97
Price Chart
Valuation
Market Cap$8.64B
P/E18.97
Forward P/E58.48
PEG0.02
P/S12.00
P/B14.44
Profitability
Total Revenue (TTM)$700M
Gross Profit (TTM)$582M
EBITDA$150M
Profit Margin9.7%
Operating Margin17%
EPS$2.97
Financial Health
Debt-to-Equity127.8%
Free Cash Flow Yield-0.16%
Growth & Risk
Revenue 5Y CAGR+278.04%
FCF 5Y CAGR-42.92%
Beta (5Y)0.80
Sharpe Ratio0.84